Traders Buy High Volume of Invivyd Call Options (NASDAQ:IVVD)

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of some unusual options trading on Thursday. Investors acquired 2,267 call options on the stock. This represents an increase of approximately 463% compared to the average daily volume of 403 call options.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on IVVD. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research report on Tuesday. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Invivyd in a research report on Monday. Finally, Morgan Stanley dropped their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $7.89.

Insider Activity at Invivyd

In other news, Director Terrance Mcguire sold 150,000 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $0.61, for a total value of $91,500.00. Following the sale, the director now directly owns 4,538,079 shares in the company, valued at approximately $2,768,228.19. This represents a 3.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold a total of 816,466 shares of company stock worth $423,214 in the last 90 days. 17.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC acquired a new position in shares of Invivyd during the second quarter worth about $421,000. Barclays PLC boosted its position in Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after acquiring an additional 75,780 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after acquiring an additional 53,499 shares in the last quarter. State Street Corp raised its holdings in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in shares of Invivyd in the third quarter worth $27,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Stock Up 12.9 %

Shares of Invivyd stock traded up $0.27 during trading on Thursday, reaching $2.38. 38,312,168 shares of the company were exchanged, compared to its average volume of 28,828,268. Invivyd has a twelve month low of $0.35 and a twelve month high of $5.10. The firm has a market capitalization of $284.93 million, a price-to-earnings ratio of -1.23 and a beta of 0.61. The business has a 50-day moving average price of $0.55 and a 200-day moving average price of $0.83.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.